Verici DX (VRCI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 9.25p
   
  • Change Today:
      0.000p
  • 52 Week High: 17.50p
  • 52 Week Low: 5.75p
  • Currency: UK Pounds
  • Shares Issued: 242.54m
  • Volume: 127,318
  • Market Cap: £22.44m
  • RiskGrade: 429

Verici enrols patients for multi-centre study ahead of forecast

By Josh White

Date: Tuesday 31 Aug 2021

LONDON (ShareCast) - (Sharecast News) - Organ transplant diagnostics developer Verici Dx announced on Tuesday that patient enrolment for a multi-centre observational clinical validation study for its lead products had concluded ahead of management expectations.
The AIM-traded firm said the early completion of enrollment reflected the fact that it remained on track to complete the validation study for the products by the end of 2021, in line with the expectations it set out in its admission document.

It said it had partnered with 11 "leading" United States and European Union centres to-date, to run a global, non-randomised study for the clinical validation of its lead products, 'Clarava' and 'Tuteva'.

The company said the study would use "next-generation" sequencing in the Verici Dx laboratory to create transcriptomic profiles, to validate performance characteristics of the lead Verici Dx signature tests.

Over the longer term, the study would also provide validation for its fibrosis test, called 'Protega'.

Patient enrolment was continuing for the validation of Protega, and was expected to complete by the third quarter of 2022.

The end points of the validation study for the product were expected to be reached up to two years after the completion of enrolment, with data expected shortly thereafter, around year-end 2024.

"I am delighted to have reached this key milestone ahead of our original expectations," said chief executive officer Sara Barrington.

"Since initial public offering, our primary focus has been on the successful prosecution of these clinical trials, as the first key step in commercialising our innovative transplant products.

"We remain on track to have our two lead products fully tested by the end of the year and look forward to reporting the data in the first quarter of 2022."

At 1006 BST, shares in Verici Dx were down 2.04% at 68.08p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Verici DX Market Data

Currency UK Pounds
Share Price 9.25p
Change Today 0.000p
% Change 0.00 %
52 Week High 17.50p
52 Week Low 5.75p
Volume 127,318
Shares Issued 242.54m
Market Cap £22.44m
RiskGrade 429

Verici DX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
39.81% below the market average39.81% below the market average39.81% below the market average39.81% below the market average39.81% below the market average
37.04% below the sector average37.04% below the sector average37.04% below the sector average37.04% below the sector average37.04% below the sector average
Price Trend
46.4% below the market average46.4% below the market average46.4% below the market average46.4% below the market average46.4% below the market average
8.77% above the sector average8.77% above the sector average8.77% above the sector average8.77% above the sector average8.77% above the sector average
Income Not Available
Growth Not Available

Verici DX Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:28 102 @ 9.00p
16:03 3,447 @ 9.25p
15:41 50,000 @ 9.30p
15:09 30,000 @ 9.30p
15:08 10,000 @ 9.00p

Verici DX Key Personnel

CEO Sara Barrington

Top of Page